Skip to content

Depression: all studies

Page 617 of 1,034: studies 6,161 to 6,170 of 10,336, newest first. Back to the depression overview

Research

Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis.

CNS Spectrums November 20, 2024 Angela T H Kwan, Moiz Lakhani, Gurkaran Singh et al. 4 citations

Inadequate response to first- and second-line pharmacological treatments for psychiatric disorders is commonly observed. Ketamine has demonstrated efficacy in treating adults with treatment-resistant depression (TRD), with additional off-label benefits reported for various psychiatric disorders. Herein, we performed a systematic review and meta-analysis to examine the therapeutic applications...

DOI: 10.1017/S1092852924000580 (opens in new tab) Full text (opens in new tab) Anxiety disorders Eating disorders Schizophrenia Substance/alcohol use disorders +5

Ayahuasca: pharmacology, safety, and therapeutic effects.

CNS Spectrums November 20, 2024 Rafael Guimarães Dos Santos, Jaime Eduardo Cecilio Hallak 13 citations

Ayahuasca is a botanical hallucinogen traditionally used for therapeutic and ritual purposes by indigenous groups from Northwestern Amazonian countries such as Brazil, Peru, Colombia, and Ecuador. Ayahuasca is made by the decoction of two plants, which are rich in the 5-HT1A/2A partial agonist dimethyltryptamine or DMT (from the leaves of the Psychotria viridis bush) and β-carbolines such as...

Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports.

Psychological Medicine November 20, 2024 B Yildirim, S S Sahin, A Gee et al. 19 citations

Psychedelic drugs are a focus of interest in the treatment of depression and other disorders but there are longstanding concerns about possible adverse psychiatric consequences. Because the relevant literature is largely informal, the seriousness of these risks is difficult to evaluate. Searches were made for case reports of schizophrenia-spectrum, affective or other psychiatric disorders after...

DOI: 10.1017/s0033291724002496 (opens in new tab) Full text (opens in new tab) Psychedelic drugs hallucinogens Psychedelics Complications Negative outcomes +7

ANÁLISE DO USO DE SUBSTÂNCIAS PSICODÉLICAS NO TRATAMENTO DA DEPRESSÃO: UMA REVISÃO INTEGRATIVA DE LITERATURA

Revista Ibero-Americana de Humanidades, Ciências e Educação November 19, 2024 Diogo Nelson Rodrigues Noronha, Flávia Avelino Galvão de MouraMoura, Gabriel Teixeira Guimarães da Fonseca et al.

O estudo buscou analisar o efeito dos psicodélicos como um meio alternativo para o tratamento do transtorno depressivo maior. Trata se de uma revisão integrativa de literatura na qual foram selecionados os descritores “psychedelic” “depression” adicionados com o operador booleano “and” entre esses nas bases de dados National Library of Medicine (PUBMED) e na Biblioteca Virtual De Saúde (BVS)....

Psilocybin Fungi Unveiled: Morphological Characteristics and Pharmacological Potentials

International Journal for Research in Applied Science and Engineering Technology November 17, 2024 Raj Nashikkar, Kavita Mane, Rajendra Patil 1 citation

Abstract: Psilocybin mushrooms, also known as "magic mushrooms," have garnered significant attention for their psychoactive properties and potential therapeutic applications. This review explores the comprehensive morphology, pharmacognostic properties, and pharmacological activities of psilocybin-producing fungi. The unique morphological characteristics of these mushrooms, including their...

Decentering as a mediator of the effect of mindfulness on emotional distress: Evidence from cross-sectional and longitudinal designs.

Psychotherapy Research November 17, 2024 Zhenzhen Wang, Xinyi Tang, Amy Hu et al. 5 citations

To investigate the role of decentering as a mediator of the effect of mindfulness/mindfulness-based intervention (MBI) on emotional distress, we conducted cross-sectional and longitudinal designs. In Study 1, a total of 998 participants with high emotional distress were included. Mindfulness, decentering, anxiety, and depression were measured at baseline. In Study 2, 688 participants with high...

DOI: 10.1080/10503307.2024.2426562 (opens in new tab) Full text (opens in new tab) Decentering Emotional distress Mediation Mindfulness-based intervention

Yoga-Based Group Intervention for Inpatients with Schizophrenia Spectrum Disorders-Feasibility, Acceptability, and Preliminary Outcomes of a Rater-Blinded Randomized Controlled Trial.

Schizophrenia Bulletin November 16, 2024 Inge Hahne, Marco Zierhut, Niklas Bergmann et al. 3 citations

The efficacy of yoga as an adjunctive treatment for schizophrenia spectrum disorders (SSD) has garnered interest. While yoga may positively influence various symptom domains, further investigation is needed due to the limited number, quality, and generalizability of studies. This study assessed the feasibility and acceptability (primary outcome) of a yoga-based group intervention (YoGI)...

DOI: 10.1093/schbul/sbae198 (opens in new tab) Full text (opens in new tab) Body mindfulness Physical exercise Psychosis Psychotic disorders

Neurobiological Changes Induced by Mindfulness and Meditation: A Systematic Review.

Biomedicines November 15, 2024 Andrea Calderone, Desirèe Latella, Federica Impellizzeri et al. 83 citations

Background and Objectives: Meditation and mindfulness, rooted in ancient traditions, enhance mental well-being by cultivating awareness and emotional control. It has been shown to induce neuroplasticity, increase cortical thickness, reduce amygdala reactivity, and improve brain connectivity and neurotransmitter levels, leading to improved emotional regulation, cognitive function, and stress...

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.

Scientific Reports November 14, 2024 Erin Wang, David S. Mathai, Natalie Gukasyan et al. 18 citations

Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumatic stress disorder. Psilocybin and MDMA may become approved medicines in the coming decade. This study assessed knowledge and attitudes regarding PAT among 879 U.S. healthcare professionals via anonymous online survey. Multivariable linear regression...

Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment.

ACS Medicinal Chemistry Letters November 14, 2024 Robert B. Kargbo 3 citations

Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in treating various mental health disorders. This Patent Highlight evaluates findings from multiple recent patents that explore novel applications of these compounds, including their use in severe psychiatric conditions such as depression, anxiety, and...

DOI: 10.1021/acsmedchemlett.4c00490 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Alternative medicine Depression treatment Therapeutic compounds +1